|Other names||Acetamidoxolutamide; Androxolutamide; GTx-007; S-4|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||441.357 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Andarine (developmental code names GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the nonsteroidal antiandrogen bicalutamide as a lead compound.
Andarine is an orally active partial agonist of the androgen receptor (AR). In intact male rats, 0.5 mg andarine daily was shown to reduce prostate weight to 79.4%, and non-significantly increased levator ani muscle weight. In castrated male rats, this dose restored only 32.5% prostate weight, but 101% levator ani muscle weight  This suggests that andarine is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist actions at the AR prevent the side effects associated with the antiandrogens traditionally used for treatment of BPH.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|